title: [Pharmacological therapy for age-related macular degeneration. Current developments and perspectives].
abstract: Current therapeutic options for age-related macular degeneration are very limited and are, at best, only capable of slowing visual loss. Because of this an intensive search for prophylactic agents capable of inhibiting the progression of this disease from early into late forms, as well as for new therapeutic approaches has been undertaken. While neuroprotective substances are hoped to prevent cellular death in this disease process, multiple substances capable of inhibiting neovascularization, such as VEGF inhibitors, are in clinical trials. Inhibitors of matrix-metalloproteinases (MMP) and chemotherapeutic agents are also being clinically tested as novel therapies for AMD. Other targets include the inhibition of toxic compound formation in lipofuscin granules such as AZ-E. What follows is an overview of different substances and their stages of development in clinical trials.
authors.affiliation: Universitäts-Augenklinik Heidelberg. frank_holz@med.uni-heidelberg.de
authors.forename: F G
authors.initials: FG
authors.lastname: Holz
authors.forename: D W
authors.initials: DW
authors.lastname: Miller
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000517:prevention & control; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D005136:Eye Proteins; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D000882:Haplorhini; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D008222:Lymphokines / Q000037:antagonists & inhibitors; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D061965:Matrix Metalloproteinase Inhibitors; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010778:Photochemotherapy; D010919:Placebos; D011506:Proteins / Q000627:therapeutic use; D051381:Rats; D015843:Serpins / Q000627:therapeutic use; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014792:Visual Acuity; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D016228:Endothelial Growth Factors; D005136:Eye Proteins; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D061965:Matrix Metalloproteinase Inhibitors; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D010919:Placebos; D011506:Proteins; D015843:Serpins; D014222:Triamcinolone Acetonide; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000099174:Pigment Epithelium-Derived Factor; C119380:lens epithelium-derived growth factor